Investing.com - Blueprint Medicines Corp (NASDAQ: BPMC) reported third quarter EPS of $-0.89, $0.07 better than the analyst estimate of $-0.96. Revenue for the quarter came in at $128.18M versus the consensus estimate of $127.56M.
Guidance
Blueprint Medicines Corp sees FY 2024 revenue of $475.00M-$480.00M versus the analyst consensus of $497.30M.
Blueprint Medicines Corp's stock price closed at $83.40. It is down -13.77% in the last 3 months and up 41.69% in the last 12 months.
Blueprint Medicines Corp saw 6 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Blueprint Medicines Corp's stock price’s past reactions to earnings here.
According to InvestingPro, Blueprint Medicines Corp's Financial Health score is "fair performance".
Check out Blueprint Medicines Corp's recent earnings performance, and Blueprint Medicines Corp's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar